Advertisement
Research Article

Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial

  • Shahin Lockman mail,

    slockman@hsph.harvard.edu

    Affiliations: Brigham and Women's Hospital, Boston, Massachusetts, United States of America, Harvard School of Public Health, Boston, Massachusetts, United States of America, Botswana Harvard School of Public Health AIDS Initiative Partnership, Gaborone, Botswana

    X
  • Michael Hughes,

    Affiliation: Harvard School of Public Health, Boston, Massachusetts, United States of America

    X
  • Fred Sawe,

    Affiliation: Kenya Medical Research Institute/Walter Reed Project and US Military HIV Research Program, Kericho, Kenya

    X
  • Yu Zheng,

    Affiliation: Harvard School of Public Health, Boston, Massachusetts, United States of America

    X
  • James McIntyre,

    Affiliation: Anova Health Institute, Johannesburg, South Africa

    X
  • Tsungai Chipato,

    Affiliation: University of Zimbabwe, Harare, Zimbabwe

    X
  • Aida Asmelash,

    Affiliation: Botswana Harvard School of Public Health AIDS Initiative Partnership, Gaborone, Botswana

    X
  • Mohammed Rassool,

    Affiliation: University of Witwatersrand, Johannesburg, South Africa

    X
  • Sylvester Kimaiyo,

    Affiliation: Moi University Faculty of Health Sciences, Eldoret, Kenya

    X
  • Douglas Shaffer,

    Affiliation: Kenya Medical Research Institute/Walter Reed Project and US Military HIV Research Program, Kericho, Kenya

    X
  • Mina Hosseinipour,

    Affiliation: Kamuzu Central Hospital, University of North Carolina Project, Lilongwe, Malawi

    X
  • Lerato Mohapi,

    Affiliation: Chris Hani Baragwanath Hospital, Johannesburg, South Africa

    X
  • Francis Ssali,

    Affiliation: Joint Clinical Research Centre, Kampala, Uganda

    X
  • Margret Chibowa,

    Affiliation: University of Alabama at Birmingham Center for Infectious Disease Research in Zambia, Lusaka

    X
  • Farida Amod,

    Affiliation: University of Kwazulu-Natal, Durban, South Africa

    X
  • Elias Halvas,

    Affiliation: University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

    X
  • Evelyn Hogg,

    Affiliation: Social & Scientific Systems, Silver Spring, Maryland, United States of America

    X
  • Beverly Alston-Smith,

    Affiliation: National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Laura Smith,

    Affiliation: Frontier Science and Technology Research Foundation, Amherst, Massachusetts, United States of America

    X
  • Robert Schooley,

    Affiliation: University of California San Diego, San Diego, California, United States of America

    X
  • John Mellors,

    Affiliation: University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

    X
  • Judith Currier,

    Affiliation: University of California Los Angeles, Los Angeles, California, United States of America

    X
  • the OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team
  • Published: June 12, 2012
  • DOI: 10.1371/journal.pmed.1001236

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.